Binding to CD155, TIGIT suppresses the function of T cells and natural killer (NK) cells, particularly within the tumor microenvironment (TME), where this immunosuppressive axis represents a critical mechanism driving tumor immune evasion. Here, PVR is linked to neoplasm.